IL-23 inhibitor lands indications for kids 6 years and up
— IL-23 inhibitor lands indications for kids 6 years and up
by Ian Ingram, Managing Editor, MedPage Today
June 29, 2026
• 2 min read
The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older, AbbVie announced.
FDA approves Skyrizi for pediatric use in psoriatic disease
What's Going On With AbbVie Stock Monday? - AbbVie (NYSE:ABBV)
FDA expands approval for Zoryve cream 0.3% to children with psoriasis as young as 2 years
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
Incyte annuncia l'opinione positiva del CHMP per Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica moderata in pazienti adulti
Uplizna approval, novel agents usher in ‘transformative time’ for IgG4-related disease
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to…
The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates…
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest…
The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced in a…
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to…
